Spinal Cord Injury Market Size in the 7MM is expected to Reach USD 1456 million by 2034.

Spinal Cord Injury Drugs Market 2034: Clinical Trials, Medication, EMA, PDMA, FDA Approval, Epidemiology, Therapies and Companies by DelveInsight     

The Spinal Cord Injury Market across the 7 major markets (7MM) — the US, EU4, UK, and Japan — is projected to grow significantly, rising from USD 354 million in 2025 to USD 1,456 million by 2034, at a CAGR of 15.4%.

In 2023, there were about 959,000 diagnosed prevalent cases of SCI in the 7MM, with the US accounting for 32%, EU4 and the UK for 56%, and Japan for 12%.

Market growth will be fueled by:

• The launch of novel therapies such as KP-100IT, Neuro-Cells, Elezanumab (ABT-555), and MT-3921.
• Increasing awareness, aging populations, and improved diagnostics leading to a rising prevalence.
• Expanding rehabilitation technologies and a strong R&D pipeline.

Currently, treatment options remain limited, with STEMIRAC being the only approved therapy (in Japan). The market presents a significant unmet need for effective and regenerative treatments.

Key players — Kringle Pharma, Neuroplast, AbbVie, and Mitsubishi Tanabe Pharma America — are actively advancing their pipelines. Notably, Kringle Pharma’s KP-100IT is in Phase III trials and expected to launch in Japan by 2025, marking a major milestone for the SCI treatment landscape.

 

DelveInsight’s Spinal Cord Injury Market Insights Report provides an in-depth analysis of current treatment practices, emerging therapies, market dynamics, and forecasted growth across the 7 major markets (US, EU4, UK, and Japan) from 2020 to 2034.

The SCI market is primarily driven by rising incidence rates, innovations in regenerative medicine, and the increasing use of neurostimulation technologies. Factors such as accidents, falls, and sports injuries are escalating demand for advanced treatment options. Emerging modalities like stem cell therapy, gene therapy, and exoskeleton-based rehabilitation are transforming the therapeutic landscape.

Despite challenges such as high treatment costs, limited curative options, and regulatory complexities, the market is poised for steady growth as ongoing R&D efforts and technological advancements continue to improve patient outcomes and expand therapeutic possibilities.

 

Request for sample report @ Spinal Cord Injury Market Insights

 

Key Takeaways from the Spinal Cord Injury Market Report

·       As per DelveInsight analysis, the spinal cord injury market is expected to grow positively at a significant CAGR during the study period (2020–2034).

·       As per the DelveInsight assessment, the total diagnosed cases of SCI in the 7MM was estimated to be ~725K cases in 2022, which is expected to increase in the forecast period (2022-2034). 

·       Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.

·       Some key therapies for spinal cord injury treatment include NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others.

 

 

Discover which therapies are expected to grab the major spinal cord injury market share @ Spinal Cord Injury Market Report

 

Spinal Cord Injury Overview

Spinal cord injury is a debilitating condition resulting from trauma or disease that damages the spinal cord, impairing motor, sensory, and autonomic functions below the level of injury. Common causes include motor vehicle accidents, falls, sports injuries, and medical conditions like tumors or infections. Spinal cord injury can be classified as complete, with total loss of function, or incomplete, where some sensation or movement remains.

The severity of Spinal cord injury depends on the location and extent of damage. Injuries to the cervical spine can result in quadriplegia, affecting all four limbs, whereas injuries to the thoracic, lumbar, or sacral regions typically cause paraplegia, involving the lower body.

Spinal cord injury Symptoms vary widely and may include paralysis, loss of sensation, pain, spasticity, and autonomic dysfunction affecting bladder, bowel, and cardiovascular regulation. Acute Spinal cord injury is a medical emergency requiring immediate stabilization to prevent further damage.

Spinal cord injury Treatment focuses on minimizing damage and promoting recovery. Initial care includes immobilization, corticosteroids to reduce inflammation, and surgical intervention when needed. Long-term management involves physical rehabilitation, occupational therapy, and assistive technologies to improve independence. Advances in regenerative medicine, including stem cell therapy, neuroprosthetics, and electrical stimulation, offer hope for improving outcomes and quality of life for individuals with Spinal cord injury.

Spinal Cord Injury Epidemiology

In 2023, there were an estimated 959,000 diagnosed prevalent cases of Spinal Cord Injury (SCI) across the seven major markets (7MM), with this number expected to increase by 2034. In the United States, approximately 308,000 prevalent cases and 19,000 new (acute) cases were reported in 2023, with both figures projected to rise over the next decade. Among these US cases, around 247,000 were male and 62,000 were female, indicating a significant gender disparity. Across the EU4 and the UK, there were about 537,000 prevalent SCI cases in 2023, with numbers anticipated to grow by 2034. Specifically, the UK reported roughly 92,000 traumatic and 14,000 non-traumatic SCI cases in 2023, expected to increase to 99,000 and 15,000, respectively, by 2034. In Japan, SCI cases were predominantly caused by falls (55%) and vehicular accidents (20%), while violence, sports injuries, and medical/surgical causes each accounted for 5%, and other factors contributed 10%. Overall, the SCI patient population across the 7MM demonstrates a rising trend, driven by increasing injury incidence, aging populations, and improved diagnostic awareness.

 

 

Spinal Cord Injury Epidemiology Segmentation

The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The spinal cord injury market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Spinal Cord Injury Cases
• Spinal Cord Injury Diagnosed Cases
• Spinal Cord Injury Gender-specific Cases
• Spinal Cord Injury Cause-specific Cases
• Total cases of SCI at Neurological Level

 

To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs 

 

Spinal Cord Injury Treatment Market 

A Spinal Cord Injury (SCI) occurs when damage to the spinal cord disrupts communication between the brain and body, often caused by accidents, falls, or violence. Individuals aged 16–30, particularly males and those engaged in high-risk activities, are most vulnerable. Symptoms depend on injury severity and site, typically resulting in loss of movement, sensation, and autonomic function, and may lead to paralysis.

Current treatment primarily focuses on acute medical intervention, surgery, and rehabilitation. Surgical decompression relieves spinal pressure, while pharmacological treatments such as methylprednisolone and other anti-inflammatory and neuroprotective agents aim to minimize damage. Physical therapy and assistive devices aid recovery, with tramadol, gabapentin, and cannabinoids used for pain management. However, there is still no definitive cure for SCI.

LYRICA (pregabalin) remains the only FDA-approved drug for neuropathic pain in SCI, while STEMIRAC, conditionally approved by Japan’s PMDA in 2018, is undergoing post-marketing evaluation, with full approval expected by 2025.

The pipeline for SCI treatment remains limited, with key candidates including KP–100IT, Neuro–Cells, MT-3921, and Elezanumab (ABT-555). These emerging therapies aim to address unmet needs beyond symptomatic relief.

In 2023, the SCI market size across the 7MM was approximately USD 345 million, projected to grow significantly through 2034:

• US: USD 146 million (2023) — expected to rise with new therapy launches.
• EU4 and UK: USD 152 million (44% of total market), led by Germany (USD 51M) and France (USD 40M).
• Japan: USD 47 million, also projected to increase.

By 2034, KP–100IT alone is expected to generate around USD 28 million in the 7MM, highlighting the market’s strong growth potential driven by innovative therapeutics and ongoing clinical advancements.

 

Key Spinal Cord Injury Therapies and Companies

·       NVG-291: NervGen Pharma

·       Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation

·       Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.

·       MT-3921: Mitsubishi Tanabe Pharma America Inc.

·       Elezanumab: AbbVie

 

Learn more about the FDA-approved drugs for spinal cord injury @ Drugs for Spinal Cord Injury Treatment 

 

Spinal Cord Injury Market Dynamics and Trends

Spinal Cord Injury Market Drivers

·       Rising Incidence of Spinal Cord Injuries - Increasing cases due to road accidents, falls, and sports injuries are expanding the patient pool and driving demand for effective therapies.

·       Advancements in Regenerative Medicine - Progress in stem cell therapy, gene therapy, and neuroregeneration research offers new possibilities for repairing nerve damage and restoring function.

·       Growing Adoption of Neurostimulation and Exoskeleton Devices - Innovative rehabilitation technologies such as robotic exoskeletons, functional electrical stimulation (FES), and brain-computer interfaces are improving patient outcomes and quality of life.

·       Rising Awareness and Early Diagnosis - Increased public awareness, better trauma care, and improved diagnostic imaging are leading to timely interventions and more accurate disease management.

·       Strong R&D Pipeline and Emerging Therapies - Promising candidates like KP-100IT, Neuro-Cells, MT-3921, and Elezanumab (ABT-555) are expected to transform the treatment landscape.

·       Supportive Government and Healthcare Initiatives - Funding for rehabilitation programs, clinical research, and assistive technology development is helping accelerate innovation in SCI care.

Spinal Cord Injury Market Barriers

·       Limited Approved Therapies - Few effective or curative options exist; STEMIRAC (Japan) and LYRICA (for neuropathic pain) remain the only approved treatments, highlighting a major unmet need.

·       High Treatment and Rehabilitation Costs - Long-term care, surgeries, and assistive technologies are financially burdensome, limiting access for many patients.

·       Regulatory and Clinical Trial Challenges - Stringent approval requirements and complex clinical endpoints slow down drug development and commercialization timelines.

·       Complex Pathophysiology of SCI - The irreversible nature of spinal cord damage and the lack of effective nerve regeneration mechanisms hinder therapeutic progress.

·       Limited Awareness in Low- and Middle-Income Regions - Inadequate trauma management infrastructure and lack of access to specialized rehabilitation centers restrict market expansion.

·       Uncertain Long-term Efficacy of Emerging Therapies - Many investigational treatments require long-term validation to confirm safety, efficacy, and sustainability of clinical benefits.

 

Scope of the Spinal Cord Injury Market Report

·       Study Period: 2020–2034

·       Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

·       Key Spinal Cord Injury Companies: NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others

·       Key Spinal Cord Injury Therapies: NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others

·       Therapeutic Assessment: Spinal Cord Injury current marketed and emerging therapies

·       Spinal Cord Injury Market Dynamics: Conjoint Analysis of Emerging Spinal Cord Injury Drugs

·       Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

·       Unmet Needs, KOL's views, Analyst's views, Spinal Cord Injury Market Access and Reimbursement

 

Discover more about spinal cord injury drugs in development @ Spinal Cord Injury Clinical Trials

 

Table of Contents

1. Spinal Cord Injury Market Key Insights

2. Spinal Cord Injury Market Report Introduction

3. Spinal Cord Injury Market Overview at a Glance

4. Spinal Cord Injury Market Executive Summary

5. Disease Background and Overview

6. Spinal Cord Injury Treatment and Management

7. Spinal Cord Injury Epidemiology and Patient Population

8. Patient Journey

9. Spinal Cord Injury Marketed Drugs

10. Spinal Cord Injury Emerging Drugs

11. Seven Major Spinal Cord Injury Market Analysis

12. Spinal Cord Injury Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.